?? WEBINAR TODAY: Alzheimer’s Disease: Early Detection and Multi-Etiology Insights from Blood-Based Immunoassays! ?? We are hours away from our upcoming #GENWebinar featuring Dr. Sterling Johnson from the University of Wisconsin-Madison, who will dive into cutting-edge multiplex blood-based immunoassays and groundbreaking Alzheimer’s research. ??? When: Wednesday, October 9 - 12:30 PM PT | 3:30 PM ET | 9:30 PM CET ?? Register Now: https://ow.ly/NlMU50TAtS5 Don’t miss this chance to be at the forefront of Alzheimer’s research and discovery! #AlzheimersResearch #EarlyDetection #Neuroscience #ClinicalTrials
Alamar Biosciences, Inc.
生物技术研究
Fremont，California 13,333 位关注者
Powering Precision Proteomics with unrivaled sensitivity and simplicity
关于我们
Alamar Biosciences is powering precision proteomics with automated, high throughput solutions for ultra-high sensitivity protein analysis across a range of multiplex levels. Our proprietary NULISA? Chemistry utilizes a novel sequential capture and release method that significantly reduces background signal and increases the sensitivity and dynamic range compared with standard approaches and allows both qPCR and NGS readouts. The NULISAseq Inflammation Panel contains 200+ important markers related to immune and inflammatory diseases and will run on our ARGO? System. This innovative platform allows for a fully automated workflow with less than 30 minutes hands on time from sample to data.
- 网站
-
https://www.alamarbio.com
Alamar Biosciences, Inc.的外部链接
- 所属行业
- 生物技术研究
- 规模
- 51-200 人
- 总部
- Fremont，California
- 类型
- 私人持股
- 创立
- 2018
地点
-
主要
获取路线
47071 Bayside Pkwy
US，California，Fremont，94538
Alamar Biosciences, Inc.员工
动态
-
#HUPO2024 is less than two weeks away! Don't miss our Industry Lunch Symposium on October 22, featuring presentations from Dr. Hanno Steen of Harvard Medical School and Boston Children's Hospital and Dr. Kristina Beeler of Biognosys. Tune in to hear how experts around the globe are using #NULISA technology to advance the field of proteomics. Swing by booth 25 to speak with our team about your research goals ?? https://ow.ly/MovI50THsoo #Proteomics #NULISA #Biomarkers
-
-
?? Join us at #HUPO2024 for a groundbreaking event in proteomics. Explore the latest advancements and research breakthroughs using #NULISA alongside experts from Biognosys during our Industry Lunch Symposium, Oct 22 at 12:15pm in the Plenary Hall. Don’t miss out on the opportunity to network and learn by visiting booth# 25. Learn more: https://ow.ly/ufnC50TGkNh #HUPO #Proteomics #immunoassay
-
Couldn't have said it better ourselves... we are very excited about Biognosys' #NULISA offering and look forward to all the amazing data to come!
Ready to push the boundaries of #biomarker discovery & quantification? Discover how our #TrueDiscovery? plasma profiling and #NULISAseq? multiplex targeted assay services can enhance your biopharma research and clinical trials. ???? The NULISAseq? targeted CNS Disease 120 and Inflammation 250 panels are? designed to detect low-abundance biomarkers like cytokines and chemokines from plasma and biofluids. These ultra-sensitive assays, available from our state-of-the-art facility in Switzerland, provide deep insights into hard-to-measure biomarkers within complex neurological and inflammatory pathways. ???? Know more: https://lnkd.in/dWCfa-87 #BiomarkerDiscovery #CNSResearch #InflammationResearch?
-
-
We are here live at the University of Cambridge today for the final leg of the Precision Biomarker Summit, held in partnership with the UK Dementia Research Institute. Looking forward to hearing from Dr. Maura Malpetti and Dr. Amanda Heslegrave present on recent studies utilizing our #NULISA and #ARGO HT technology for high sensitivity protein detection in #dementia and other CNS diseases – now available at the UK DRI Biomarker Factory! How does NULISA work? Learn more ??https://ow.ly/BXEk50TAKLv
-
-
?? WEBINAR ALERT: Alzheimer’s Disease: Early Detection and Multi-Etiology Insights from Blood-Based Immunoassays! ?? Did you know detecting Alzheimer's before cognitive decline starts is key for effective treatment? Join us for an insightful #GENWebinar featuring Dr. Sterling Johnson from the University of Wisconsin-Madison, who will dive into cutting-edge multiplex blood-based immunoassays and groundbreaking Alzheimer’s research. ?? What You'll Learn: - New biomarkers and technologies like NULISA? to detect AD early. - Insights from the Wisconsin Registry for Alzheimer’s Prevention (WRAP). - Understanding the complex mix of etiologies, such as vascular disease, alpha synuclein proteinopathy, and more. - Opportunities for earlier intervention and enhanced patient stratification. ? Plus, hear from Alex Forrest-Hay about Alamar’s latest innovations! ??? When: Wednesday, October 9 - 12:30 PM PT | 3:30 PM ET | 9:30 PM CET ?? Register Now: https://ow.ly/NlMU50TAtS5 Don’t miss this chance to be at the forefront of Alzheimer’s research and discovery! #AlzheimersResearch #EarlyDetection #Neuroscience #ClinicalTrials
-
-
Congratulations Carlos Cruchaga and team! Exciting to continue to see great data coming out of your lab. We’re glad #NULISA has made an impact on your efforts and look forward to our continued partnership.
Excited to share the latest paper from the lab, published today Cell Press "CSF proteomics identifies early changes in autosomal dominant Alzheimer’s disease". https://lnkd.in/g5-tqMQJ We identified proteins that capture disease changes 15-20 years before clinical symptoms. The identified proteins are capturing three stages: early stage (stress response, glutamate metabolism, neuron mitochondrial damage), middle stage (neuronal death, apoptosis), and late presymptomatic stage (microglial changes, cell communication). We applied ML/AI to identify a subset of seven proteins to create novel predictive models that are superior that CSF Aβ and ptau to identify symptomatic carriers, but also can identity pre-symptomatic individuals. Although autosomal dominant AD (ADAD) proteomic profile is similar, we identified unique proteomic signatures for ADAD, including EPHA4, DLK2 or TNFRSF21 that have opposite direction between sporadic and ADAD.
-
-
?? New Breakthrough in TBI Research! ?? Our understanding of Traumatic Brain Injury (TBI) just took a leap forward! A recent publication in Brain (Sept 26, 2024) explores how high-dimensional proteomic analysis can offer a more detailed understanding of TBI’s complex pathophysiology. ?? Key Highlights: - Novel proteomic assays (including #NULISA) identified 16 proteins with TBI-specific plasma expression changes. - Proteins related to neurodegeneration, inflammation, and cell metabolism were found to correlate with patterns of injury. - This study revealed subgroups of TBI patients based on protein expression, showing how proteomics can enhance classification and potentially guide future treatments. ?? With implications for prognosis and treatment development, this research utilizing the #NULISA Platform provides exciting new insights into the mechanisms of TBI, paving the way for more targeted therapeutic approaches. Read more: https://lnkd.in/gy--3UbF Congrats to Drs. Lucia M Li,?Amanda Heslegrave,?Henrik Zetterberg,?Neil Graham,?Karl Zimmerman,?Eyal Soreq,?Thomas Parker,?Elena Garbero,?Frederico Moro,?Sandra Magnoni,?Guido Bertolini,?David J Loane,?and David J Sharp! #TBI #Proteomics #Neuroscience #Research #TraumaticBrainInjury #BrainHealth #ScienceInnovation #Healthcare #proteomics #immunoassay
-
??Proud to be a Gold Sponsor and join up with FaponBiotech and Stanford Healthcare Innovation Lab for the Proteomics From Genes to Functions Symposium at Stanford University. If you are attending, the latest #NULISA technology will be discussed as part of Dr. Holden Maecker's presentation: Cross-platform comparison of highly-sensitive immunoassays for inflammatory markers in a COVID-19 cohort at 3:45pm PT. Learn more about NULISA: https://lnkd.in/eyJh_PGT #proteomics #immunoassay
-
-
Finishing off a busy week continuing our Precision Biomarker Summit in partnership with the UK Dementia Research Institute at Cardiff University / Prifysgol Caerdydd. Dr. Van Dien Nguyen and Dr. Amanda Heslegrave presented on recent studies utilizing our #NULISA and #ARGO HT technology for early detection of fluid biomarkers and monitoring of proteomic changes associated with dementia, Alzheimers, and other CNS diseases. Dive into groundbreaking discussions on our ultra-sensitive NULISA? Platform – now available at the UK DRI Biomarker Factory! How does NULISA work? Learn more ??https://ow.ly/51Wq50Twu8E
-